U.S. markets closed

Cellectis S.A. (ALCLS.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
11.58-0.19 (-1.61%)
At close: 5:35PM CEST

Cellectis S.A.

8, rue de la Croix Jarry
Paris 75013
France
33 1 81 69 16 00
http://www.cellectis.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees272

Key Executives

NameTitlePayExercisedYear Born
Dr. Andre ChoulikaCo-Founder, CEO & Director1.15MN/A1965
Dr. David J. D. SourdiveCo-Founder, Exec. VP of Strategic Initiatives & Director476.63kN/A1967
Mr. Eric DutangChief Financial OfficerN/AN/A1974
Mr. Jean Charles EpinatChief Technological OfficerN/AN/AN/A
Ms. Marie-Bleuenn TerrierGen. Counsel & Sec. of the Board of DirectorsN/AN/A1982
Ms. Jennifer MooreSr. VP of PRN/AN/AN/A
Ms. Kyung Nam-WortmanExec. VP & Chief HR OfficerN/AN/A1970
Dr. Philippe Duchateau Ph.D.Chief Scientific OfficerN/AN/A1963
Mr. Stephan ReynierChief Regulatory & Pharmaceutical Compliance OfficerN/AN/A1969
Simon HarnestSr. VP of Corp. Strategy & Fin.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. The company was founded in 1999 and is headquartered in Paris, France.

Corporate Governance

Cellectis S.A.’s ISS Governance QualityScore as of July 1, 2021 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.